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Th e annual meeting of the American Society of Human 
Genetics is a major  ­ some would say overwhelming  ­ 
conference that aims to present the state of the fi eld as a 
whole, with presentations on nearly all aspects of human 
genetics. Th is year, the meeting had a record number of 
nearly 7,000 participants, with approximately 450 scien­
tifi c presentations and over 3,200 posters. In addition, 
more than 200 vendors presented their products, includ­
ing all major DNA sequencing companies, bioinformatic 
services for data analysis, and clinics specializing in 
genetic medicine. In order to navigate this scientifi c 
maze, the organizers developed a smartphone application 
to allow users to browse abstracts based on schedule, 
presenter, and topic, and to generate a snapshot of the 
current events at the conference. Intriguing buzzwords 
had participants running back and forth between rooms 
to hear speakers from parallel sessions.
Some of the most frequent terms used throughout the 
meeting, according to quantitative text analysis of 
#ASHG2012 tweets, were ‘rare’ and ‘common’ with both 
almost equally represented. Indeed, in the spirit of the US 
presidential election, which coincided with the fi rst day 
of the meeting, there seemed to be a common and rare 
variant party division. Entire sessions were devoted 
exclusively to either class of variant, such as ‘GWAS from 
head to toe’ and ‘Cancer genetics I: rare variants’. In an 
attempt to fi nd a bipartisan resolution, one session was 
dedicated to ‘Common variants, rare variants, and 
everything in between’, and presented the advantages of 
an integrated approach that examines association signals 
of both variant classes. Interestingly, several talks showed 
that such integrative studies based on whole exome 
sequencing can simultaneously replicate known genome­
wide association study (GWAS) signals and uncover a 
distinct set of genes that harbor rare etiological 
variations.
The interpretation gap
A recurrent issue throughout the meeting was the gap 
between data generation and data interpretation, espe­
cially for rare variants. Th is challenge is exacerbated by 
the application of sequencing in the clinic, where 
evaluation of pathogenic variants and incidental fi ndings 
may determine the course of treatment. A signifi cant 
number of talks described potential techniques to over­
come this interpretation gap. Some speakers, such as 
Heidi Rehm (Harvard Medical School, USA) suggested 
the development of specifi c databases for clinical inter­
pre tation. Others, including Marc Greenblatt (University 
of Vermont, USA), focused on the development of 
standards for variant interpretation. Another set of 
presen tations described the recent successes of commu­
nity­based interpretation contests, such as Boston 
Children’s Hospital’s CLARITY challenge and Berkeley’s 
Critical Assessment of Genome Interpretation.
Th e main challenge when studying rare variants is that 
robust statistical inference of their eff ects in case­control 
studies requires a large amount of sequencing data. 
Daniel MacArthur (Massachusetts General Hospital, 
USA) suggested a brute force approach that includes 
sequencing a large number of individuals, postulating 
that ‘in order to understand one genome, we need to 
sequence tens of thousands of genomes.’
Family studies: a shortcut to analyze rare variants
Other speakers suggested alternative, more effi  cient 
approaches to rare variant interpretation. In fact, one of 
the prevailing themes at this year’s meeting was the 
renewed interest in large pedigrees and isolated popu la­
tions to assess the eff ect of rare variants on common 
traits. Michael Province (Washington University, USA) 
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presented one potential problem of the brute force 
approach in a session centered on family studies as a 
means to investigate complex traits. Citing recent studies 
about rapid population growth in humans, he noted that 
the number of extremely rare alleles in the population is 
much higher than thought. Even doubling the sample size 
does not help very much, as the new sample will simply 
present new rare alleles, rather than add statistical power. 
As an alternative, he suggested focusing on large pedi­
grees, where the allelic diversity is smaller: ‘pedigrees 
make the needle [rare variants] in the haystack bigger’ 
and thus easier to find. Further, the extensive identity­by­
descent (IBD) between individuals helps to distinguish 
true rare variant calls from sequencing errors and pro­
vides a means to verify novel alleles in multiple related 
individuals.
Robert Elston (Case Western Reserve University, USA) 
was the most insistent about the current appeal of family 
studies in a special session recognizing his 80th birthday. 
He went so far as to say that ‘somehow, for the last decade 
or so, we were misguided into thinking that families were 
not necessary, and we have seen epidemiologists having a 
ball with case­control studies and honestly believing that 
they are doing genetic research!’ Elston did say that 
family studies may one day in the distant future be 
dispen sable, but maintained that, for now, it is crucial to 
study variants in the context of inheritance, rather than 
simply as DNA.
From interpretation bottlenecks to genetic 
bottlenecks
In addition to the renewed interest in family studies, 
several speakers highlighted the value of studying isolated 
populations. Jeffrey O’Connell (University of Maryland, 
USA) described a study of complex traits in the Amish 
population, in which he found a steady increase in the 
inbreeding coefficient in the last 200 years. He showed 
that, on average, a pair of individuals is as genetically 
similar as first cousins once removed. With such a strong 
genetic bottleneck, rare variants that segregate in the 
European population may increase by orders of 
magnitude in the Amish population, enabling robust 
statistical inference about their roles. To stress this point, 
he concluded his talk with a reminder that ‘we study the 
Amish not because they are different but because they 
are us.’
William Scott (University of Miami, USA) and Cornelia 
van Duijn (Erasmus University Rotterdam, the Nether­
lands) presented an integrative approach for identifying 
pathogenic variants of complex disorders in isolated 
populations. Their method starts with linkage analysis to 
find large segments that segregate with a given pheno­
type, followed by whole exome sequencing to pinpoint 
the pathogenic variant in the linkage interval. This 
tech nique showed mixed results. They were able to 
uncover a rare pathogenic variant in a study of depression 
but found no coherent signal in a study of Parkinson’s 
disease, suggesting a potential role for non­coding variants.
Other presenters tried to reconcile the advantages of 
both traditional case­control and family studies. Hua 
Zhou (UCLA, USA) discussed combining genome­wide 
association mapping with pedigrees for quantitative trait 
locus analysis. Similarly, Richard Spritz (University of 
Colorado Denver, USA) presented an approach that 
integrates GWAS with the sequencing of siblings under a 
linkage peak. Elizabeth Thompson (University of Wash­
ing ton, USA) discussed using IBD within and between 
pedigrees, echoing Robert Elston’s emphasis on the need 
for information on relatedness. She concluded that, 
eventually, pedigree and population studies will be 
equivalent, in the sense that we can use techniques for 
analyzing IBD to obtain the same information.
Conclusion
In the past few years, we have witnessed the emergence 
of large­scale sequencing projects to study common 
diseases, such as the NHGRI’s ClinSeq study, NHLBI’s 
Exome Sequencing Project, and The Personal Genome 
Project. The renewed interest in large pedigrees and 
isolated populations for complex trait studies at this 
year’s meeting was refreshing. Several speakers high­
lighted the advantages of such designs in interpreting the 
role of rare genetic variations. In addition to facilitating 
the ascertainment of multiple individuals with the same 
rare variant, the substantial IBD in the samples promotes 
imputation and increases confidence in the sequencing 
results. Further, these designs afford a set of comple men­
tary tools, including linkage analysis and heritability 
measurements, that can accelerate genetic investigation.
By definition, personalized medicine entails drawing 
conclusions based on the study of a single genome from 
the general population. Despite the tremendous advan­
tages of family and isolated population study designs, we 
should also remember that they do not entirely reflect the 
general population. For instance, the substantial IBD 
between participants in these studies increases the likeli­
hood of overestimating the effect of a variant due to 
epistasis, a point that was emphasized in the opening talk 
at ASHG 2010 by Eric Lander (Broad Institute, USA). 
Another potential complication is the sampling of indi­
viduals from narrow environmental conditions, which is 
more prone to confounding gene­environment inter­
actions. Evidently, nothing comes free in human genetics. 
Each study design has its own limitations and advantages, 
necessitating an integrative approach to bridge the inter­
pretation gap and effectively handle today’s population­
scale datasets.
Meeting tweets are available online at #ashg2012.
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